These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 18055314)

  • 1. [Interim analyses].
    Kramar A; Paoletti X
    Bull Cancer; 2007 Nov; 94(11):965-74. PubMed ID: 18055314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Children's Oncology Group routinely applies "lack of efficacy" interim monitoring to its randomized clinical trials.
    Anderson JR; Krailo M
    Am J Bioeth; 2011 Mar; 11(3):18-9. PubMed ID: 21400379
    [No Abstract]   [Full Text] [Related]  

  • 3. Design of randomized controlled trials.
    Stanley K
    Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
    [No Abstract]   [Full Text] [Related]  

  • 4. Methodology of superiority vs. equivalence trials and non-inferiority trials.
    Christensen E
    J Hepatol; 2007 May; 46(5):947-54. PubMed ID: 17412447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring clinical trials: issues and controversies regarding confidentiality.
    Fleming TR; Ellenberg S; DeMets DL
    Stat Med; 2002 Oct; 21(19):2843-51. PubMed ID: 12325100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.
    Korn EL; Freidlin B
    Am J Bioeth; 2011 Mar; 11(3):2-10. PubMed ID: 21400374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence of underpowered randomized clinical trials in rheumatology.
    Keen HI; Pile K; Hill CL
    J Rheumatol; 2005 Nov; 32(11):2083-8. PubMed ID: 16265683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?
    Ellenberg SS; George SL
    Stat Med; 2004 May; 23(10):1503-5. PubMed ID: 15122727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current controversies in data monitoring for clinical trials.
    Pocock SJ
    Clin Trials; 2006; 3(6):513-21. PubMed ID: 17170035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent Data Monitoring Committee in the U.S. Cancer Cooperative Group setting?
    Bryant J
    Stat Med; 2004 May; 23(10):1507-11. PubMed ID: 15122728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment.
    Whitehead J; Matsushita T
    Stat Med; 2003 Mar; 22(5):677-87. PubMed ID: 12587099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporating intermediate binary responses into interim analyses of clinical trials: a comparison of four methods.
    Whitehead A; Sooriyarachchi MR; Whitehead J; Bolland K
    Stat Med; 2008 May; 27(10):1646-66. PubMed ID: 17886243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The independent statistician for data monitoring committees.
    DeMets DL; Fleming TR
    Stat Med; 2004 May; 23(10):1513-7. PubMed ID: 15122729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sample size estimation in phase III cancer clinical trials.
    Curran D; Sylvester RJ; Hoctin Boes G
    Eur J Surg Oncol; 1999 Jun; 25(3):244-50. PubMed ID: 10336801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Data monitoring committees, interim analysis and early termination in paediatric trials.
    Fernandes RM; van der Lee JH; Offringa M
    Acta Paediatr; 2011 Oct; 100(10):1386-92. PubMed ID: 21434998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, operation, and interpretation of clinical trials.
    Pihlstrom BL; Barnett ML
    J Dent Res; 2010 Aug; 89(8):759-72. PubMed ID: 20581353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Futility approaches to interim monitoring by data monitoring committees.
    Demets DL
    Clin Trials; 2006; 3(6):522-9. PubMed ID: 17170036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing phase III or IV trials for vaccines: choosing between individual or cluster randomised trial designs.
    Vaucher P
    Vaccine; 2009 Mar; 27(13):1928-31. PubMed ID: 19368773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.